{"id":16854,"date":"2024-09-29T09:29:35","date_gmt":"2024-09-29T07:29:35","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2024\/09\/29\/deleting-trim33-in-myeloid-cells-improves-the-efficiency-of-radiotherapy-through-an-interferon-beta-dependent-anti-tumor-immune-response\/"},"modified":"2024-09-29T09:29:35","modified_gmt":"2024-09-29T07:29:35","slug":"deleting-trim33-in-myeloid-cells-improves-the-efficiency-of-radiotherapy-through-an-interferon-beta-dependent-anti-tumor-immune-response","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2024\/09\/29\/deleting-trim33-in-myeloid-cells-improves-the-efficiency-of-radiotherapy-through-an-interferon-beta-dependent-anti-tumor-immune-response\/","title":{"rendered":"Deleting Trim33 in myeloid cells improves the efficiency of radiotherapy through an interferon beta dependent anti-tumor immune response"},"content":{"rendered":"<div>\n<p>Cancer Immunol Res. 2024 Sep 26. doi: 10.1158\/2326-6066.CIR-24-0026. Online ahead of print.<\/p>\n<p>ABSTRACT<\/p>\n<p>Radiotherapy (RT) triggers an immune response that contributes to anti-tumor effects. Induction of interferon beta (IFN-\u03b2) is a key event in this immunogenicity of RT. We have previously shown that TRIM33, a chromatin reader, restrains IFN-\u03b2 expression in Toll-like receptor-activated myeloid cells. Here, we explored whether deleting Trim33 in myeloid cells might improve the radio-induced immune response, and subsequent efficiency of RT. We first established that Trim33-\/- bone marrow-derived macrophages showed increased expression of IFN-\u03b2 in response to direct irradiation, or to treatment with irradiated cancer cells, further supporting our hypothesis. We then tested the efficiency of a single dose RT in three subcutaneous and one orthotopic tumor models. In all situations, myeloid deletion of Trim33 led to a significantly improved response after RT, leading to a complete and durable response in most of the treated mice bearing orthotopic oral tumors. This effect required the IFN-I pathway, and the presence of CD8+ T lymphocytes, but not NK cells. In addition, cured mice were capable of rejecting a secondary tumor challenge, demonstrating an in situ vaccination effect. We conclude that deleting Trim33 in myeloid cells improves RT efficiency, through a mechanism involving the IFN-I pathway and the immune response. Our work suggests that myeloid Trim33 is a host factor affecting the tumor response to RT, thus representing a new potential therapeutic target for modifying RT responses.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39325415\/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20240929032735&amp;v=2.18.0.post9+e462414\">39325415<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-24-0026\">10.1158\/2326-6066.CIR-24-0026<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2024 Sep 26. doi: 10.1158\/2326-6066.CIR-24-0026. Online ahead of print. ABSTRACT Radiotherapy (RT) triggers an immune response that contributes to anti-tumor effects. Induction of interferon beta (IFN-\u03b2) is a key event in this immunogenicity of RT. We have previously shown that TRIM33, a chromatin reader, restrains IFN-\u03b2 expression in Toll-like receptor-activated myeloid cells. &#8230; <a title=\"Deleting Trim33 in myeloid cells improves the efficiency of radiotherapy through an interferon beta dependent anti-tumor immune response\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2024\/09\/29\/deleting-trim33-in-myeloid-cells-improves-the-efficiency-of-radiotherapy-through-an-interferon-beta-dependent-anti-tumor-immune-response\/\" aria-label=\"Read more about Deleting Trim33 in myeloid cells improves the efficiency of radiotherapy through an interferon beta dependent anti-tumor immune response\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-16854","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/16854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=16854"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/16854\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=16854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=16854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=16854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}